Clinical trial NCT02239731: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
Official title: A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rash Due to Epidermal Growth Factor Receptor Inhibitors
Keywords: EGFRI
Epidermal Growth Factor Receptor Inhibition
Skin toxicity
Topical
Doxycycline
Foam
Phase II
Cetuximab
Panitumumab
Vectibix
Erbitux
Rash
Lead sponsor: Vyne Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2014-09-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.

Detailed description: This is a phase II multicenter, randomized, double blind, vehicle controlled clinical study to evaluate the safety, tolerability and efficacy of Doxycycline Foam 4% for the prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects with Cancer Receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis.

The study consists of a screening visit, a treatment period where patients will be treated topically on the face twice daily for 5 weeks. A post-treatment follow up visit (4 weeks after end of treatment), will be performed only for subjects who have experienced unresolved possibly-related or related adverse events at the end of the treatment. Seven days after randomization and study drug initiation, subjects will start their EGFRI treatment.

Eligibility criteria: Inclusion Criteria:

1. Age 18 years and older
2. Subjects with any cancer receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis.
3. Scheduled to start Cetuximab or Panitumumab treatment;
4. Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or with a negative subunit hCG pregnancy test immediately prior to study entry.
5. Able to understand and provide signed informed consent.
6. Ability to reliably apply topical FDX104 and vehicle twice a day to the appropriate part of the face
7. Willingness to minimize sun exposure for 5 weeks from randomization
8. ECOG performance status 0-2.

Exclusion Criteria:

1. Prior allergic reaction or severe intolerance to Doxcycycline and/or other tetracyclines.
2. Prior allergic reaction or severe intolerance to soy or coconut oil
3. Cutaneous metastases on the face or might spread to the face.
4. The presence of any active skin disease (e.g., eczema), tattoos or other problems at application site, (i.e., located on the face) that, in the investigator's opinion, could confound the evaluation of the rash or make topical application unacceptable
5. Hair on the face (e.g beard) which would interfere with the application of the study drug or its evaluation.
6. ANC \<1,500/mm3 (or\<1.5x109/L), or Platelet count \< 100,000/mm3 (or \<100x109/L)
7. Abnormal renal functions: Serum creatinine \>1.6 mg/dL or 142umol/L (SI units) or calculated estimated creatinine clearance \<40 ml/min1.73 m2 based on Cockcroft and Gault formula.
8. Abnormal hepatic functions: Serum Aspartate transaminase (AST) or alanine tansaminase (ALT) \>5 institutional upper limit of normal (ULN). Or Total billirubin \> 2 x institutional ULN or \>5 x institutional ULN if documented liver metastasis.
9. Any clinically significant safety laboratory results that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study
10. Any clinically significant finding on the physical examination that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study
11. Systemic lupus erythematosus
12. Undergoing any current biological treatment for cancer other than the prescribed EGFRI
13. Treatment with topical antibiotics, anti-acne medication and other topical treatments on the face within 14 days prior to treatment start. Use of topical corticosteroids within 2 weeks prior to baseline; only mild to moderate topical steroids are allowed outside the head and neck area. The area should not exceed 10% of the whole body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed in short term use (≤15 consecutive days).
14. Treatment with systemic antibiotics 7 days prior to treatment start.
15. Known or suspected pregnancy, or lactation or planned pregnancy (females)
16. Previous enrolment in a clinical trial involving investigational drug or a medical device within 30 days before provision of written informed consent for the study
17. Subjects who are mentally or physically unable to comply with all aspects of the study.

Primary outcomes:
measure: To investigate the safety and tolerability of FDX104 in cancer patients receiving EGFRI
timeFrame: 9 weeks
Secondary outcomes:
Other outcomes:
measure: Reduction of skin toxicity by FDX104 in cancer patients treated with EGFRI
timeFrame: 9 weeks
Locations:
city: Be'er-Sheva
country: Israel
facility: Soroka Medical Center
city: Haifa
country: Israel
facility: Rambam Medical Center
city: Jerusalem
country: Israel
facility: Hadassah Medical Center
city: Petah-Tikva
country: Israel
facility: Rabin Medical Center
city: Rishon LeZion
country: Israel
facility: Assaf Harofeh medical center
city: Tel Aviv
country: Israel
facility: Sourasky medical center
city: Tel Hashomer
country: Israel
facility: Sheba medical center
Study officials:
affiliation: Sourasky Medical center, Tel-aviv, Israel
name: Ravit Geva, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sheba Medical Center
name: Einat Shacham Shmueli, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Assaf Harofeh medical center, Beer Yaakov, Israel
name: Nirit Yarom, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Rambam Health Care Campus
name: Valerya Semenysty, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hadassah Medical Organization
name: Ayala Hubert, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Soroka University Medical Center
name: Alexander Gluzman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Rabin Medical Center
name: Hadas Prag Nave, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shacham Shmueli E, Geva R, Yarom N, Hubert A, Keynan R, Kedem TH, Eini M, Tamarkin D, Shirvan M. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. Support Care Cancer. 2019 Aug;27(8):3027-3033. doi: 10.1007/s00520-018-4600-8. Epub 2019 Jan 4.